Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5851523A · kind A · utility
8Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 1994 |
| Grant date | Dec 22, 1998 |
| Priority date | — |
| Expiry date | Aug 15, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.